article · ESMO Open
Background: The TOPAZ-1 trial showed improved overall survival (OS) and progression-free survival (PFS) for pts with advanced BTC.However, we still lack predictive biomarkers for immunotherapy benefits and have limited data on the clinical significance of genomic features. Methods:The study involved pts with unresectable, locally advanced, or metastatic BTC receiving CGD at 39 clinical sites in 11 countries from July 2021 to December 2023.Genomic analyses of primary tumors were conducted locally using various nextgeneration sequencing assays.Additionally, to test the impact of the prognostic index, outcomes from the CGD cohort were compared to a historical cohort receiving only CG.The data was collected prospectively from 17 centers in Italy between March 2006 and December 2022.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.esmoop.2025.104269
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
